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Abstract: 
Equine mammary tumors are uncommon, and relatively sparse 
histopathological and molecular data exists. The present study describes 
the histopathological features of seven such tumors, which exhibited 
infiltrative growth, intermediate to high mitotic rates, and focally extensive 
necrosis. The tumors exhibited variably strong staining for vimentin and 
cytokeratin 14, and frequently weak cytoplasmic staining for pan-
cytokeratin. E-cadherin expression was strong. Interestingly, subgroups of 
the tumors exhibited strong nuclear staining for estrogen receptor α. Three 
of seven tumors exhibited nuclear expression of the transcription factor 
STAT3, suggesting that STAT3 was transcriptionally active. Rare to absent 
nuclear STAT3 expression was observed in carcinomas exhibiting moderate 
to intense staining for cytokeratin 14. This investigation confirms previous 
investigators’ assertions that equine mammary tumors have a malignant 
phenotype. A subset of the equine mammary tumors exhibited estrogen 
receptor α expression, suggesting that these tumors may potentially have 
similar molecular characteristics to their feline and canine counterparts. 
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Abstract 
Equine mammary tumors are uncommon, and relatively sparse histopathological and 
molecular data exists. The present study describes the histopathological features of seven 
such tumors, which exhibited infiltrative growth, intermediate to high mitotic rates, and 
focally extensive necrosis. The tumors exhibited variably strong staining for vimentin and 
cytokeratin 14, and frequently weak cytoplasmic staining for pan-cytokeratin. E-cadherin 
expression was strong. Interestingly, subgroups of the tumors exhibited strong nuclear 
staining for estrogen receptor α. Three of seven tumors exhibited nuclear expression of the 
transcription factor STAT3, suggesting that STAT3 was transcriptionally active. Rare to 
absent nuclear STAT3 expression was observed in carcinomas exhibiting moderate to intense 
staining for cytokeratin 14. This investigation confirms previous investigators’ assertions that 
equine mammary tumors have a malignant phenotype. A subset of the equine mammary 
tumors exhibited estrogen receptor α expression, suggesting that these tumors may potentially 
have similar molecular characteristics to their feline and canine counterparts. 
 
 
Keywords: estrogen receptor; equine; horse; mammary tumor; STAT3. 
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Domestic herbivores develop mammary tumors at a much lower frequency than 
domestic carnivores. Mammary tumors in mares are rare, in spite of the fact that horses in the 
United Kingdom generally represent a companion animal group rather than a production 
animal species, and as such often reach an advanced age. In general, equine mammary tumors 
are carcinomas. They tend to be locally aggressive and metastasize to the regional lymph 
nodes and other organs 
2
 
3
 
8
 
9
 
11
. The scarcity of equine mammary tumors is exemplified by 
the fact that these tumors have mainly been documented by means of case reports 
3
 
8
 
2
 and 
small case series 
9
 
11
. Molecular characterisation, which is gaining increasing prominence in 
small animal mammary oncology 
13
, has so far been limited, although staining for estrogen 
receptor and progesterone receptor has been attempted 
11
 and successfully demonstrated in 
one mare 
2
. 
 
The purpose of the current study was to characterise the morphology of equine 
mammary tumors in conjunction with expression of selected intermediate filaments and the 
adhesion molecule E-cadherin. Estrogen receptor α (ERα) status was assessed in view of the 
previously reported estrogen receptor positive case 
2
 and the possible prognostic implications. 
Finally, nuclear expression of STAT3 in equine mammary tumors was interrogated as a 
potential future prognostic marker. The signal transducers and activators of transcription 
(STATs) are transcription factors that influence cellular differentiation, proliferation, survival 
and death. STAT3 is constitutively activated in approximately 50% of primary human breast 
tumors 
1
, and may predict a poor prognosis in ERα positive cases 
7
. STATs are generally 
activated by transient phosphorylation, prior to dimerization and translocation to the nucleus 
to control transcription and thus nuclear localization may indicate transcriptional activity. 
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Methods 
A search of the histopathology and necropsy databases at Beaufort Cottage 
Laboratories from 2006 to 2013 (totalling 15,789 equine submissions) identified six cases of 
equine mammary carcinoma and no cases of equine mammary hyperplasia or adenomas. A 
further equine mammary carcinoma was identified from the histopathology submission 
records of Bridge Pathology Ltd, which comprised 470 equine histopathology submissions 
received between 2008 and 2013. Representative histological sections were examined and the 
molecular characteristics of the tumors were investigated. 
 
Three-micrometer sections of paraffin-embedded material were mounted on positively 
charged slides (Snowcoat, Surgipath Europe Ltd). Sections were stained with hematoxylin 
and eosin, and immunohistochemical staining for pan-cytokeratin, cytokeratin 14, and 
vimentin was carried out using a routine protocol employing an automated 
immunohistochemistry system (Dako Autostainer, Dako). Diaminobenzidine solution was 
used to demonstrate peroxidise activity, and slides were counterstained with haematoxylin. 
Diluent was utilised as a negative control. Immunohistochemical staining for nuclear STAT3 
expression (horse Nos. 1-4) was carried out manually. Immunofluorescence staining for 
nuclear localisation of STAT3 (horse Nos. 5-7), ERα, and E-cadherin was performed 
manually. Standard protocols were followed and are described elsewhere 
4
. The antibodies 
and dilutions employed are detailed in Supplemental Table 1. Appropriate species- and 
isotype-matched immunoglobulins were utilised as negative controls for manual staining. 
Quiescent mammary tissue removed from a mare at necropsy provided positive control tissue 
for pan-cytokeratin, cytokeratin 14, vimentin and E-cadherin staining. 
 
Clinical and histopathological findings 
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Limited signalment and clinical data was available. For five of the seven mares, the 
age range was 10 years to 20 years (median 11 years). Two were cobs, one was a 
Thoroughbred and for the others breed was not known. Information on parity and lactation 
status was not available. In some cases the mass had been present for some time (horse Nos. 
1 and 2). In two cases (horse Nos. 1 and 5) the lesion was originally diagnosed and treated as 
mastitis. In one instance (horse No. 3) unilateral mastectomy was performed, but generally 
treatment was limited or not recorded. Euthanasia was frequently undertaken following the 
results of biopsy. In one case (horse No. 2), necropsy was carried out, and metastatic spread 
to the sublumbar, prefemoral and caudal cervical lymph nodes, lung, spleen and liver was 
identified and confirmed histologically.  
 
For each case, histopathological and immmunohistochemical/immunofluorescent 
findings are detailed in Supplemental Table 2. Representative images are displayed in Figs. 
1-10. The seven equine mammary tumors exhibited a range of histological appearances 
predominantly characterised by a tubulopapillary pattern (Fig. 1), a solid pattern, or a 
combination of the two. Two tumors (horse Nos. 1 and 6) exhibited a prominent comedone 
pattern of necrosis (Figs. 2 and 6; horse No. 1) similar to that previously recorded 
8
. All 
tumors exhibited an infiltrative phenotype similar to that already documented 
3
 
8
 
9
 
11
. 
Infiltration of the tumors with lymphocytes, plasma cells, macrophages and neutrophils was 
frequent. The aggressive phenotype of the tumors was reflected by an intermediate to high 
mitotic rate (Supplemental Table 2). In addition to horse No. 2, where metastatic spread was 
confirmed at necropsy, in horse No. 3 aggregates of neoplastic cells were clearly visible 
within lymphatic vessels adjacent to the main mass (Fig. 3).  
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Moderate to intense vimentin staining of the majority of the neoplastic cells was 
observed in four of the cases examined (Fig. 4). Pan-cytokeratin staining was generally mild 
to moderate in intensity, in spite of strong staining in adjacent non-neoplastic mammary 
tissue (Fig. 5). It was noted that in control quiescent mammary tissue, the pan-cytokeratin 
antibody employed preferentially stained luminal epithelial cells, with weaker or absent 
staining observed in cells with location and morphology consistent with basal epithelial cells 
(Supplemental Fig. 1). Consequently, a specific basal cytokeratin 14 stain was also employed 
to determine if the tumors exhibited a basal phenotype (Supplemental Fig. 2 and Fig. 6). Two 
out of seven cases (Nos. 1 and 6) exhibited intense staining for cytokeratin 14 (Fig. 6) whilst 
less than 20% of the neoplastic cells examined exhibited moderate levels of cytokeratin 14 
staining in horse Nos. 3 and 7. 
 
Three out of seven cases (horse Nos. 1, 4 and 5) exhibited strong nuclear staining for 
ERα (Figs. 7 and 8), whilst three of the seven equine mammary carcinomas (horse Nos. 4, 5 
and 7) exhibited strong nuclear expression of STAT3 (Fig. 9 and 10). Expression of the 
intercellular adhesion molecule E-cadherin was strong in all seven cases (Figs. 7 and 10).  
 
Discussion 
Where available, clinical history suggested that the mammary masses had frequently 
been present for some time, and two cases (horse Nos. 1 and 5) had clinical characteristics 
suggestive of mastitis. A presenting clinical suspicion of mastitis has been described 
previously 
3
 and mastitis may be a secondary complication of a mammary tumor 
11
.  
 
A previous case report has demonstrated staining for estrogen receptor and 
progesterone receptor in an invasive micropapillary carcinoma in a mare 
2
. In the present 
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report, we utilise immunofluorescence to demonstrate notable levels of nuclear ERα staining 
in three of the seven carcinomas examined. Assessment of estrogen receptor positivity is 
fundamental to breast cancer diagnosis and prognostication in humans, and expression has 
been confirmed in both canine mammary tumors and their feline counterparts. The 
demonstration of nuclear ERα expression in equine mammary tumors is exciting as it 
suggests that hormonal influences may also potentially play a role in the pathogenesis of a 
subset of mammary tumors in herbivorous domestic species, in spite of their differing clinical 
characteristics compared to their canine counterparts.  
 
ERα expression status did not correlate with a particular histopathological pattern in 
the present case series. However, although it is not possible to draw firm conclusions from 
analysis of seven cases, it is interesting that ERα positive staining tended to be observed in 
tumors with weak or absent vimentin staining. This correlates with recent evidence 
suggesting that in humans, vimentin expression, which tends to be associated with epithelial-
mesenchymal transition (EMT), is higher in triple-negative breast cancers than in other 
subtypes such as those expressing estrogen receptor 
12
.  
 
Pan-cytokeratin staining in these tumors was generally mild to moderate in intensity, 
which is in contrast to a previous report where equine mammary ductal carcinoma cells were 
strongly positive for pan-cytokeratin (clone Lu-5) 
3
. Notably even in Horse No. 6, in which 
approximately 60% of the neoplastic cells exhibited mild to moderate cytoplasmic expression 
of cytokeratin, staining was considerably weaker in the neoplastic cells than in adjacent non-
neoplastic mammary tissue. In non-neoplastic tissue, luminal epithelia exhibited intense 
staining with the pan-cytokeratin antibody, whilst weaker staining was noted in cells with 
location and morphology consistent with basal epithelia. Consequently, a specific basal 
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cytokeratin 14 stain was also employed. Two mammary carcinomas (horse Nos. 1 and 6) 
exhibited intense staining with cytokeratin 14, whilst horse No. 3 exhibited a moderate 
degree of staining, suggesting a basal origin for these tumors. In two cases (horse Nos. 3 and 
6), cytokeratin 14 expression correlated with an absence of ERα expression, as would be 
expected. However, curiously, in horse No. 1 intense cytokeratin 14 expression coincided 
with ERα positivity. Although uncommon, a small proportion of human basal-like breast 
cancers are reported to exhibit ERα positivity, determined by gene expression profiling 
5
. 
 
Membranous expression of E-cadherin was strong in all seven cases; in the one 
carcinoma that was known to have metastasised (Horse No. 2) expression remained strong in 
both the primary tumor and pulmonary metastases. This is consistent with the human breast 
cancer literature, where it has been demonstrated that E-cadherin expression in metastatic 
ductal carcinomas may be the same intensity or stronger than in the equivalent primary 
masses 
6
. It is traditionally considered most likely that E-cadherin expression is down-
regulated during the process of epithelial-mesenchymal transition (EMT) during metastasis, 
with subsequent re-expression in metastatic foci. However, it has recently been suggested that 
in some instances of human inflammatory breast carcinoma E-cadherin may also be up-
regulated in tumor microemboli, favouring intravasation 
10
. The immunofluorescence 
findings in the present study could be compatible with either hypothesis. 
 
Interestingly, strong nuclear localisation of STAT3 was detected in three of the seven 
equine mammary carcinomas (horse Nos. 4, 5 and 7), suggesting a potential role for STAT3 
activity in a subset of equine mammary carcinomas. These cases exhibited a tubulo-papillary 
to solid growth pattern and in two cases exhibited convincing ERα expression, tentatively 
suggesting that a more luminal phenotype might be associated with nuclear STAT3 
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expression. The three cases which exhibited moderate to intense positive staining for 
cytokeratin 14 (horse Nos. 1, 3 and 6), indicating a more basal phenotype, exhibited rare to 
absent nuclear STAT3 expression, potentially further supporting this interpretation. In human 
breast cancer, some authors have suggested a correlation between STAT3 expression and the 
luminal subtype 
7
, although this is not consistently demonstrable 
1
. 
 
 A major limitation of this study is that the small number of available cases precludes 
any meaningful correlations or prognostic assertions. Given the rarity of equine mammary 
tumors, wide-ranging multi-centre collaborations are required to build up adequate case 
material for any such prognostic or molecular relationships to be adequately interrogated. 
Such investigations would also require comprehensive clinical follow-up. Although all of the 
cases for which outcome data was available were euthanized following diagnosis, the records 
available do not indicate whether this decision was based on clinical condition of the mare, or 
prognostic advice from the attendant veterinary surgeon.  
 
Taken together, our histopathological data confirms previous reports that equine 
mammary tumors have an invasive and malignant phenotype. Importantly, the histological 
phenotype, and molecular characteristics appear to be heterogeneous, with variable 
expression of intermediate filaments, ERα, and nuclear STAT3. The role of STAT3 activity 
in equine mammary tumors merits further investigation, particularly to confirm or refute the 
potential inverse correlation with cytokeratin 14 expression. Our findings also confirm that a 
subset of equine mammary tumors exhibit ERα expression, which suggests that these tumors 
may have similar molecular characteristics to their feline and canine counterparts.  
 
Supplemental material is available online. 
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Figure legends 
 
Figures 1-10. Mammary carcinoma, horse, mammary gland. Figures 1-3 HE. Figure 1. 
Tubulopapillary pattern; horse No. 5. Figure 2. Solid with comedone pattern of necrosis; 
horse No.1. Figure 3. Tumor cells present within a lymphatic vessel (black arrow); horse No. 
3. Figure 4. IHC for vimentin shows that the majority of the neoplastic cells in this 
tubulopapillary to solid carcinoma exhibit strong cytoplasmic expression (black arrowhead); 
horse No. 2. Figure 5. IHC for pan-cytokeratin shows that approximately 60% of the 
neoplastic cells in this tubulopapillary to solid carcinoma exhibit mild to moderate 
cytoplasmic expression; horse No. 6.  Intense cytoplasmic expression is observed in adjacent 
non-neoplastic mammary tissue (red arrow; positive internal control tissue). Figure 6. IHC 
for cytokeratin 14 shows that the vast majority of the neoplastic cells exhibit intense 
cytoplasmic expression; horse No. 1. Figure 7. Nuclear expression of estrogen receptor alpha 
(ERα) and membranous expression of E-cadherin in a solid carcinoma; horse No. 1. 
Immunofluorescence staining for ERα (red), E-cadherin (E-cad) (green) and DNA (Hoechst; 
blue). Figure 8. Nuclear expression of estrogen receptor alpha (ERα) in a solid carcinoma; 
horse No. 4. Immunofluorescence staining for ERα (red), and DNA (Hoechst; blue). Figure 
9. IHC for STAT3 shows both cytoplasmic and nuclear localization (arrowhead); horse No. 4. 
Figure 10. Nuclear localization of STAT3 (white arrow) in an equine mammary tumor. Not 
all neoplastic cells exhibit nuclear STAT3 (white arrowhead) corroborating specificity of 
staining; horse No. 7. Immunofluorescence staining for STAT3 (red), E-cadherin (E-cad) 
(green) and DNA (Hoechst; blue).  
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Supplemental Figures S1 and S2. Quiescent mammary tissue, horse, mammary gland. 
Supplemental Figure S1. IHC for pan-cytokeratin demonstrates that pan-cytokeratin 
preferentially stains luminal epithelial cells compared to basal epithelial cells (arrow). 
Supplemental Figure S2. IHC for cytokeratin 14 stains basal epithelial cells.  
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Abstract 
Equine mammary tumors are uncommon, and relatively sparse histopathological and 
molecular data exists. The present study describes the histopathological features of seven 
such tumors, which exhibited infiltrative growth, intermediate to high mitotic rates, and 
focally extensive necrosis. The tumors exhibited variably strong staining for vimentin and 
cytokeratin 14, and frequently weak cytoplasmic staining for pan-cytokeratin. E-cadherin 
expression was strong. Interestingly, subgroups of the tumors exhibited strong nuclear 
staining for estrogen receptor α. Three of seven tumors exhibited nuclear expression of the 
transcription factor STAT3, suggesting that STAT3 was transcriptionally active. Rare to 
absent nuclear STAT3 expression was observed in carcinomas exhibiting moderate to intense 
staining for cytokeratin 14. This investigation confirms previous investigators’ assertions that 
equine mammary tumors have a malignant phenotype. A subset of the equine mammary 
tumors exhibited estrogen receptor α expression, suggesting that these tumors may potentially 
have similar molecular characteristics to their feline and canine counterparts. 
 
 
Keywords: estrogen receptor; equine; horse; mammary tumor; STAT3. 
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Domestic herbivores develop mammary tumors at a much lower frequency than 
domestic carnivores. Mammary tumors in mares are rare, in spite of the fact that horses in the 
United Kingdom generally represent a companion animal group rather than a production 
animal species, and as such often reach an advanced age. In general, equine mammary tumors 
are carcinomas. They tend to be locally aggressive and metastasize to the regional lymph 
nodes and other organs 
2
 
3
 
8
 
9
 
11
. The scarcity of equine mammary tumors is exemplified by 
the fact that these tumors have mainly been documented by means of case reports 
3
 
8
 
2
 and 
small case series 
9
 
11
. Molecular characterisation, which is gaining increasing prominence in 
small animal mammary oncology 
13
, has so far been limited, although staining for estrogen 
receptor and progesterone receptor has been attempted 
11
 and successfully demonstrated in 
one mare 
2
. 
 
The purpose of the current study was to characterise the morphology of equine 
mammary tumors in conjunction with expression of selected intermediate filaments and the 
adhesion molecule E-cadherin. Estrogen receptor α (ERα) status was assessed in view of the 
previously reported estrogen receptor positive case 
2
 and the possible prognostic implications. 
Finally, nuclear expression of STAT3 in equine mammary tumors was interrogated as a 
potential future prognostic marker. The signal transducers and activators of transcription 
(STATs) are transcription factors that influence cellular differentiation, proliferation, survival 
and death. STAT3 is constitutively activated in approximately 50% of primary human breast 
tumors 
1
, and may predict a poor prognosis in ERα positive cases 
7
. STATs are generally 
activated by transient phosphorylation, prior to dimerization and translocation to the nucleus 
to control transcription and thus nuclear localization may indicate transcriptional activity. 
 
Page 17 of 34
http://mc.manuscriptcentral.com/vetpath
Veterinary Pathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
4 
 
Methods 
A search of the histopathology and necropsy databases at Beaufort Cottage 
Laboratories from 2006 to 2013 (totalling 15,789 equine submissions) identified six cases of 
equine mammary carcinoma and no cases of equine mammary hyperplasia or adenomas. A 
further equine mammary carcinoma was identified from the histopathology submission 
records of Bridge Pathology Ltd, which comprised 470 equine histopathology submissions 
received between 2008 and 2013. Representative histological sections were examined and the 
molecular characteristics of the tumors were investigated. 
 
Three-micrometer sections of paraffin-embedded material were mounted on positively 
charged slides (Snowcoat, Surgipath Europe Ltd). Sections were stained with hematoxylin 
and eosin, and immunohistochemical staining for pan-cytokeratin, cytokeratin 14, and 
vimentin was carried out using a routine protocol employing an automated 
immunohistochemistry system (Dako Autostainer, Dako). Diaminobenzidine solution was 
used to demonstrate peroxidise activity, and slides were counterstained with haematoxylin. 
Diluent was utilised as a negative control. Immunohistochemical staining for nuclear STAT3 
expression (horse Nos. 1-4) was carried out manually. Immunofluorescence staining for 
nuclear localisation of STAT3 (horse Nos. 5-7), ERα, and E-cadherin was performed 
manually. Standard protocols were followed and are described elsewhere 
4
. The antibodies 
and dilutions employed are detailed in Supplemental Table 1. Appropriate species- and 
isotype-matched immunoglobulins were utilised as negative controls for manual staining. 
Quiescent mammary tissue removed from a mare at necropsy provided positive control tissue 
for pan-cytokeratin, cytokeratin 14, vimentin and E-cadherin staining. 
 
Clinical and histopathological findings 
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Limited signalment and clinical data was available. For five of the seven mares, the 
age range was 10 years to 20 years (median 11 years). Two were cobs, one was a 
Thoroughbred and for the others breed was not known. Information on parity and lactation 
status was not available. In some cases the mass had been present for some time (horse Nos. 
1 and 2). In two cases (horse Nos. 1 and 5) the lesion was originally diagnosed and treated as 
mastitis. In one instance (horse No. 3) unilateral mastectomy was performed, but generally 
treatment was limited or not recorded. Euthanasia was frequently undertaken following the 
results of biopsy. In one case (horse No. 2), necropsy was carried out, and metastatic spread 
to the sublumbar, prefemoral and caudal cervical lymph nodes, lung, spleen and liver was 
identified and confirmed histologically.  
 
For each case, histopathological and immmunohistochemical/immunofluorescent 
findings are detailed in Supplemental Table 2. Representative images are displayed in Figs. 
1-10. The seven equine mammary tumors exhibited a range of histological appearances 
predominantly characterised by a tubulopapillary pattern (Fig. 1), a solid pattern, or a 
combination of the two. Two tumors (horse Nos. 1 and 6) exhibited a prominent comedone 
pattern of necrosis (Figs. 2 and 6; horse No. 1) similar to that previously recorded 
8
. All 
tumors exhibited an infiltrative phenotype similar to that already documented 
3
 
8
 
9
 
11
. 
Infiltration of the tumors with lymphocytes, plasma cells, macrophages and neutrophils was 
frequent. The aggressive phenotype of the tumors was reflected by an intermediate to high 
mitotic rate (Supplemental Table 2). In addition to horse No. 2, where metastatic spread was 
confirmed at necropsy, in horse No. 3 aggregates of neoplastic cells were clearly visible 
within lymphatic vessels adjacent to the main mass (Fig. 3).  
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Moderate to intense vimentin staining of the majority of the neoplastic cells was 
observed in four of the cases examined (Fig. 4). Pan-cytokeratin staining was generally mild 
to moderate in intensity, in spite of strong staining in adjacent non-neoplastic mammary 
tissue (Fig. 5). It was noted that in control quiescent mammary tissue, the pan-cytokeratin 
antibody employed preferentially stained luminal epithelial cells, with weaker or absent 
staining observed in cells with location and morphology consistent with basal epithelial cells 
(Supplemental Fig. 1). Consequently, a specific basal cytokeratin 14 stain was also employed 
to determine if the tumors exhibited a basal phenotype (Supplemental Fig. 2 and Fig. 6). Two 
out of seven cases (Nos. 1 and 6) exhibited intense staining for cytokeratin 14 (Fig. 6) whilst 
less than 20% of the neoplastic cells examined exhibited moderate levels of cytokeratin 14 
staining in horse Nos. 3 and 7. 
 
Three out of seven cases (horse Nos. 1, 4 and 5) exhibited strong nuclear staining for 
ERα (Figs. 7 and 8), whilst three of the seven equine mammary carcinomas (horse Nos. 4, 5 
and 7) exhibited strong nuclear expression of STAT3 (Fig. 9 and 10). Expression of the 
intercellular adhesion molecule E-cadherin was strong in all seven cases (Figs. 7 and 10).  
 
Discussion 
Where available, clinical history suggested that the mammary masses had frequently 
been present for some time, and two cases (horse Nos. 1 and 5) had clinical characteristics 
suggestive of mastitis. A presenting clinical suspicion of mastitis has been described 
previously 
3
 and mastitis may be a secondary complication of a mammary tumor 
11
.  
 
A previous case report has demonstrated staining for estrogen receptor and 
progesterone receptor in an invasive micropapillary carcinoma in a mare 
2
. In the present 
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report, we utilise immunofluorescence to demonstrate notable levels of nuclear ERα staining 
in three of the seven carcinomas examined. Assessment of estrogen receptor positivity is 
fundamental to breast cancer diagnosis and prognostication in humans, and expression has 
been confirmed in both canine mammary tumors and their feline counterparts. The 
demonstration of nuclear ERα expression in equine mammary tumors is exciting as it 
suggests that hormonal influences may also potentially play a role in the pathogenesis of a 
subset of mammary tumors in herbivorous domestic species, in spite of their differing clinical 
characteristics compared to their canine counterparts.  
 
ERα expression status did not correlate with a particular histopathological pattern in 
the present case series. However, although it is not possible to draw firm conclusions from 
analysis of seven cases, it is interesting that ERα positive staining tended to be observed in 
tumors with weak or absent vimentin staining. This correlates with recent evidence 
suggesting that in humans, vimentin expression, which tends to be associated with epithelial-
mesenchymal transition (EMT), is higher in triple-negative breast cancers than in other 
subtypes such as those expressing estrogen receptor 
12
.  
 
Pan-cytokeratin staining in these tumors was generally mild to moderate in intensity, 
which is in contrast to a previous report where equine mammary ductal carcinoma cells were 
strongly positive for pan-cytokeratin (clone Lu-5) 
3
. Notably even in Horse No. 6, in which 
approximately 60% of the neoplastic cells exhibited mild to moderate cytoplasmic expression 
of cytokeratin, staining was considerably weaker in the neoplastic cells than in adjacent non-
neoplastic mammary tissue. In non-neoplastic tissue, luminal epithelia exhibited intense 
staining with the pan-cytokeratin antibody, whilst weaker staining was noted in cells with 
location and morphology consistent with basal epithelia. Consequently, a specific basal 
Page 21 of 34
http://mc.manuscriptcentral.com/vetpath
Veterinary Pathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
8 
 
cytokeratin 14 stain was also employed. Two mammary carcinomas (horse Nos. 1 and 6) 
exhibited intense staining with cytokeratin 14, whilst horse No. 3 exhibited a moderate 
degree of staining, suggesting a basal origin for these tumors. In two cases (horse Nos. 3 and 
6), cytokeratin 14 expression correlated with an absence of ERα expression, as would be 
expected. However, curiously, in horse No. 1 intense cytokeratin 14 expression coincided 
with ERα positivity. Although uncommon, a small proportion of human basal-like breast 
cancers are reported to exhibit ERα positivity, determined by gene expression profiling 
5
. 
 
Membranous expression of E-cadherin was strong in all seven cases; in the one 
carcinoma that was known to have metastasised (Horse No. 2) expression remained strong in 
both the primary tumor and pulmonary metastases. This is consistent with the human breast 
cancer literature, where it has been demonstrated that E-cadherin expression in metastatic 
ductal carcinomas may be the same intensity or stronger than in the equivalent primary 
masses 
6
. It is traditionally considered most likely that E-cadherin expression is down-
regulated during the process of epithelial-mesenchymal transition (EMT) during metastasis, 
with subsequent re-expression in metastatic foci. However, it has recently been suggested that 
in some instances of human inflammatory breast carcinoma E-cadherin may also be up-
regulated in tumor microemboli, favouring intravasation 
10
. The immunofluorescence 
findings in the present study could be compatible with either hypothesis. 
 
Interestingly, strong nuclear localisation of STAT3 was detected in three of the seven 
equine mammary carcinomas (horse Nos. 4, 5 and 7), suggesting a potential role for STAT3 
activity in a subset of equine mammary carcinomas. These cases exhibited a tubulo-papillary 
to solid growth pattern and in two cases exhibited convincing ERα expression, tentatively 
suggesting that a more luminal phenotype might be associated with nuclear STAT3 
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expression. The three cases which exhibited moderate to intense positive staining for 
cytokeratin 14 (horse Nos. 1, 3 and 6), indicating a more basal phenotype, exhibited rare to 
absent nuclear STAT3 expression, potentially further supporting this interpretation. In human 
breast cancer, some authors have suggested a correlation between STAT3 expression and the 
luminal subtype 
7
, although this is not consistently demonstrable 
1
. 
 
 A major limitation of this study is that the small number of available cases precludes 
any meaningful correlations or prognostic assertions. Given the rarity of equine mammary 
tumors, wide-ranging multi-centre collaborations are required to build up adequate case 
material for any such prognostic or molecular relationships to be adequately interrogated. 
Such investigations would also require comprehensive clinical follow-up. Although all of the 
cases for which outcome data was available were euthanized following diagnosis, the records 
available do not indicate whether this decision was based on clinical condition of the mare, or 
prognostic advice from the attendant veterinary surgeon.  
 
Taken together, our histopathological data confirms previous reports that equine 
mammary tumors have an invasive and malignant phenotype. Importantly, the histological 
phenotype, and molecular characteristics appear to be heterogeneous, with variable 
expression of intermediate filaments, ERα, and nuclear STAT3. The role of STAT3 activity 
in equine mammary tumors merits further investigation, particularly to confirm or refute the 
potential inverse correlation with cytokeratin 14 expression. Our findings also confirm that a 
subset of equine mammary tumors exhibit ERα expression, which suggests that these tumors 
may have similar molecular characteristics to their feline and canine counterparts.  
 
Supplemental material is available online. 
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Figure legends 
 
Figures 1-10. Mammary carcinoma, horse, mammary gland. Figures 1-3 HE. Figure 1. 
Tubulopapillary pattern; horse No. 5. Figure 2. Solid with comedone pattern of necrosis; 
horse No.1. Figure 3. Tumor cells present within a lymphatic vessel (black arrow); horse No. 
3. Figure 4. IHC for vimentin shows that the majority of the neoplastic cells in this 
tubulopapillary to solid carcinoma exhibit strong cytoplasmic expression (black arrowhead); 
horse No. 2. Figure 5. IHC for pan-cytokeratin shows that approximately 60% of the 
neoplastic cells in this tubulopapillary to solid carcinoma exhibit mild to moderate 
cytoplasmic expression; horse No. 6.  Intense cytoplasmic expression is observed in adjacent 
non-neoplastic mammary tissue (red arrow; positive internal control tissue). Figure 6. IHC 
for cytokeratin 14 shows that the vast majority of the neoplastic cells exhibit intense 
cytoplasmic expression; horse No. 1. Figure 7. Nuclear expression of estrogen receptor alpha 
(ERα) and membranous expression of E-cadherin in a solid carcinoma; horse No. 1. 
Immunofluorescence staining for ERα (red), E-cadherin (E-cad) (green) and DNA (Hoechst; 
blue). Figure 8. Nuclear expression of estrogen receptor alpha (ERα) in a solid carcinoma; 
horse No. 4. Immunofluorescence staining for ERα (red), and DNA (Hoechst; blue). Figure 
9. IHC for STAT3 shows both cytoplasmic and nuclear localization (arrowhead); horse No. 4. 
Figure 10. Nuclear localization of STAT3 (white arrow) in an equine mammary tumor. Not 
all neoplastic cells exhibit nuclear STAT3 (white arrowhead) corroborating specificity of 
staining; horse No. 7. Immunofluorescence staining for STAT3 (red), E-cadherin (E-cad) 
(green) and DNA (Hoechst; blue).  
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Supplemental Figures S1 and S2. Quiescent mammary tissue, horse, mammary gland. 
Supplemental Figure S1. IHC for pan-cytokeratin demonstrates that pan-cytokeratin 
preferentially stains luminal epithelial cells compared to basal epithelial cells (arrow). 
Supplemental Figure S2. IHC for cytokeratin 14 stains basal epithelial cells.  
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Supplemental table 1 
Antibodies employed for immunohistochemistry and immunofluorescence. 
 
Antibody and species Dilution Manufacturer Catalogue number 
Mouse anti-human 
vimentin 
1:500 Dako M0725 
Mouse anti-human 
cytokeratin. Clone 
MNF116. Reacts 
with cytokeratins 5, 
6, 8, 17 and probably 
also 19. 
1:100 Dako M0821 
Mouse anti-
cytokeratin 14 
[LL002] 
1:200 Abcam ab7800 
Rabbit anti-mouse 
STAT3 
1:50 Cell Signaling 
Technology 
#9132 
Rabbit anti-mouse 
estrogen receptor α
a
 
1:50 Santa Cruz 
Biotechnology 
sc-542 
Mouse anti-bovine 
estrogen receptor α
b
 
1:50 Santa Cruz 
Biotechnology 
sc-787 
Mouse anti-human 
E-cadherin 
1:200 BD Biosciences 610182 
 
a
 Cases 1-4 only. 
b 
Cases 5-7 only. 
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Supplemental table 2 
Histopathological data for seven equine mammary tumors.  
Case Histological 
classification 
Mitotic 
rate 
primary 
tumor 
per 10 
hpf P
a
n
-
cy
to
k
er
a
ti
n
 
C
y
to
k
er
a
ti
n
 
1
4
 
Vimentin E-
Cadherin 
Estrogen 
receptor 
Nuclear 
Stat3 
1 Solid 
carcinoma 
with 
comedone 
pattern of 
necrosis 
8  - ++ +/- ++ ++ +/-  
Rare 
individual 
cells 
2 Tubulo-
papillary to 
solid 
carcinoma 
23 +/- - ++ ++ +/- 
Rare 
individual 
cells  
- 
Occasional 
positive 
cells in 
pulmonary 
metastases 
3 Solid 
carcinoma 
with 
extensive 
necrosis 
17 + + + ++ - - 
4 Tubulo-
papillary to 
solid 
carcinoma 
~10* + NP - ++ ++ ++ 
5 Tubulo-
papillary 
carcinoma 
38 ++ - - ++ ++ ++ 
6 Tubulo-
papillary to 
solid 
carcinoma 
with 
multifocal 
comedone 
pattern of 
necrosis 
9 ++ ++ ++ ++ - - 
7 Tubulo-
papillary to 
solid 
carcinoma 
with 
intraductular 
growth 
pattern 
10 +/- + + ++ - ++ 
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Hpf  = high power fields (400x magnification). 
* Only small biopsy pieces available. 
NP = not performed; insufficient tissue. 
– indicates no positive staining in tissue planes examined. +/- indicates rare positive staining 
individual cells or multifocal areas of very weak staining. + indicates less than 20% of 
neoplastic cells exhibit moderate levels of staining. ++ indicates that 20% or more of 
neoplastic cells exhibit moderate levels of staining. 
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